Outcome after allogeneic stem cell transplantation with haploidentical versus HLA-matched donors in patients with higher-risk MDS

• Published in: Bone marrow transplantation (Basingstoke) 2023-05, Vol.58 (5), p.534-543
• Main Authors: Michel, Claire, Robin, Marie, Morisset, Stephane, Blaise, Didier, Maertens, Johan, Chevalier, Patrice, Castilla-Llorente, Cristina, Forcade, Edouard, Ceballos, Patrice, Yakoug-Agha, Ibrahim, Poire, Xavier, Carre, Martin, Bay, Jacques-Olivier, Beguin, Yves, Loschi, Michael, Huynh, Anne, Guillerm, Gaëlle, François, Sylvie, Mear, Jean-Baptiste, Duléry, Rémy, Suarez, Felipe, Bilger, Karin, Cornillon, Jérôme, Chalandon, Yves, Maillard, Natacha, Labussière-Wallet, Hélène, Charbonnier, Amandine, Turlure, Pascal, Berceanu, Ana, Chantepie, Sylvain, Maury, Sébastien, Bazarbachi, Ali, Menard, Anne-Lise, Nguyen-Quoc, Stephanie, Rubio, Marie-Thérèse, D’Aveni, Maud
• Format: Article
• Language: English
• Subjects: 13/100; 692/699; 692/699/1541/1990/1673; Abnormalities; Acute Disease; Allografts; Cell Biology; Donors; Graft vs Host Disease; Graft vs Host Disease - etiology; Graft-versus-host reaction; Hematology; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cell Transplantation - methods; Hematopoietic stem cells; Histocompatibility antigen HLA; Human health sciences; Humans; Hématologie; Internal Medicine; Karyotypes; Leukemia; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Acute - complications; Life Sciences; Medicine; Medicine & Public Health; Mud; Myelodysplastic syndrome; Myelodysplastic syndromes; Public Health; Retrospective Studies; Risk; Sciences de la santé humaine; Siblings; Stem cell transplantation; Stem Cells; Survival; Tissue Donors; Transplantation; Transplantation Conditioning; Transplantation Conditioning - methods; Transplantation, Homologous; Transplantation, Homologous - methods; Unrelated Donors
• ISSN: 0268-3369; 1476-5365; 1476-5365
• DOI: 10.1038/s41409-023-01931-7

Allogeneic hematopoietic stem cell transplantation remains the best curative option for higher-risk myelodysplastic syndrome. The presence of monosomal karyotype and/or complex karyotype abnormalities predicts inferior survival after allo-SCT in MDS patients. Haploidentical allo-SCT has been increasingly used in acute leukemia (AL) and has similar results as using HLA-matched donors, but data on higher-risk MDS is sparse. We compared outcomes in 266 patients with higher-risk MDS after HLA-matched sibling donor (MSD, n  = 79), HLA-matched unrelated donor (MUD, n  = 139) and HLA haploidentical donor (HID, n  = 48) from 2010 to 2019. Median donor age differed between the three groups ( p